Serum concentrations of galectin-3 in patients with cardiac syndrome X

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 259-263

  Bozcali, Evin ^a   Polat, Veli ^b   Aciksari, Gonul ^b   Opan, Selcuk ^b   Bayrak, Ibrahim Halil ^b   Paker, Nurcan ^c   Karakaya, Osman ^b  

^a KOÇ UNIVERSITY   (Turkey)

^b BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Duzen Laboratories   (Turkey)

Author keywords

Cardiac syndrome X; Fibrosis; Galectin 3; Inflammation

Indexed keywords

C REACTIVE PROTEIN; GALECTIN 3; GLUCOSE; URIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; SYNDROME X; AGED; ANGIOCARDIOGRAPHY; BLOOD; CARDIOVASCULAR SYSTEM; CASE CONTROL STUDY; COMPLICATION; EXERCISE TEST; FIBROSIS; INFLAMMATION; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR SYSTEM; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EXERCISE TEST; FEMALE; FIBROSIS; GALECTIN 3; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MICROCIRCULATION; MICROVASCULAR ANGINA; MIDDLE AGED;

EID: 84907686007     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.014     Document Type: Article

References (29)

1. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635.
2. Calvier L., Miana M., Reboul P., Cachofeiro V., Martinez-Martinez E., de Boer R.A., Poirier F., Lacolley P., Zannad F., Rossignol P., Lopez-Andres N. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33:67-75.
3. Joo H.G., Goedegebuure P.S., Sadanaga N., Nagoshi M., Bernstorff W., Eberlein T.J. Expression and function of galectin-3, a β-galactoside-binding protein activated T lymphocytes. J.Leukoc. Biol. 2001, 69:555-564.
4. Inohara H., Akahani S., Raz A. Galectin-3 stimulates cell proliferation. Exp. Cell Res. 1998, 245:294-302.
5. De Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11:811-817.
6. Papaspyridonos M., McNeill E., de Bono J.P., Smith A., Burnand K.G., Channon K.M., Greaves D.R. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler. Thromb. Vasc. Biol. 2008, 28:433-440.
7. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., Kobold A.C.M., van Gilst W.H., Hillege H.L., Bakker S.J.L., van der Harst P. The fibrosis marker galectin-3 and outcome in the general population. J.Intern. Med. 2012, 272:55-64.
8. Tsai T.H., Sung P.H., Chang L.T., Sun C.K., Yeh K.H., Chung S.Y., Chua S., Chen Y.L., Wu C.J., Chang H.W., Ko S.F., Yip H.K. Value and level of galectin-3 acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J.Atheroscler. Thromb. 2012, 19:1073-1082.
9. Kemp H.G. Left ventricular function in patients with anginal syndrome and normal coronary arteriograms. Am. J. Cardiol. 1973, 32:375-376.
10. Cannon R.O., Epstein S.E. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am. J. Cardiol. 1988, 61:1338-1343.
11. Chimenti C., Sale P., Verardo R., Cicalini S., Petrosillo N., Russo M.A., Fedele F., Frustaci A. High prevalence of intramural coronary infection in patients with drug-resistant cardiac syndrome X: comparison with chronic stable angina and normal controls. Heart 2010, 96:1926-1931.
12. Yamamoto S., James T.N., Kawamura K., Nobuyoshi M. Cardiocytic apoptosis and capillary endothelial swelling as morphological evidence of myocardial ischemia in ventricular biopsies from patients with angina and normal coronary arteriograms. Coron. Artery Dis. 2002, 13:25-35.
13. Ho J.E., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R.S., Larson M.G., Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J.Am. Coll. Cardiol. 2012, 60:1249-1256.
14. Van Kimmenade R.R., Januzzi J.L., Ellinor P.T., Sharma U.C., Bakker J.A., Low A.F., Martinez A., Crijns H.J., MacRae C.A., Menheere P.P., Pinto Y.M. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J.Am. Coll. Cardiol. 2006, 48:1217-1224.
15. Lok D.J., Van Der Meer P., de la Porte P.W., Lipsic E., Van Wijngaarden J., Hillege H.L., van Veldhuisen D.J. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol. 2010, 99:323-328.
16. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 2010, 12:826-832.
17. Lok D.J., Lok S.I., Bruggink-Andre de la Porte P.W., Badings E., Lipsic E., van Wijngaarden J., de Boer R.A., van Veldhuisen D.J., van der Meer P. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol. 2013, 102:103-110.
18. Grandin E.W., Jarolim P., Murphy S.A., Ritterova L., Cannon C.P., Braunwald E., Morrow D.A. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin. Chem. 2012, 58:267-273.
19. Falcone C., Lucibello S., Mazzucchelli I., Bozzini S., D'Angelo A., Schirinzi S., Totaro R., Falcone R., Bondesan M., Pelissero G. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int. J. Immunopathol. Pharmacol. 2011, 24:905-913.
20. Menini S., Iacobini C., Ricci C., Blasetti Fantauzzi C., Salvi L., Pesce C.M., Relucenti M., Familiari G., Taurino M., Pugliese G. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc. Res. 2013, 10.1093/cvr/cvt206.
21. Arar C., Gaudin J.C., Capron L., Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett. 1998, 430:307-311.
22. MacKinnon A.C., Liu X., Hadoke P.W., Miller M.R., Newby D.E., Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013, 23:654-663.
23. Arroyo-Espliguero R., Mollichelli N., Avanzas P., Zouridakis E., Newey V.R., Nassiri D.K., Kaski J.C. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur. Heart J. 2003, 24:2006-2011.
24. Li J.J., Zhu C.G., Nan J.L., Li J., Li Z.C., Zeng H.S., Gao Z., Qin X.W., Zhang C.Y. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine 2007, 40:172-176.
25. Eroglu S., Sade L.E., Yildirir A., Demir O., Bozbas H., Muderrisoglu H. Serum levels of C-reactive protein and uric acid in patients with cardiac syndrome X. Acta Cardiol. 2009, 64:207-211.
26. Gulati M., Cooper-DeHoff R.M., McClure C., Johnson B.D., Shaw L.J., Handberg E.M., Zineh I., Kelsey S.F., Arnsdorf M.F., Black H.R., Pepine C.J., Merz C.N. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch. Intern. Med. 2009, 169:843-850.
27. Bugiardini R., Manfrini O., Pizzi C., Fontana F., Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004, 109:2518-2523.
28. Zorc-Pleskovic R., Vraspir-Porenta O., Zorc M., Milutinovic A., Petrovic D. Inflammatory changes in small blood vessels in the endomyocardium of cardiac syndrome X in female patients with increased C-reactive protein. Folia Biol. 2008, 54:30-32.
29. Suzuki H., Takeyama Y., Koba S., Suwa Y., Katagiri T. Small vessel pathology and coronary hemodynamics in patients with microvascular angina. Int. J. Cardiol. 1994, 43:139-150.